Difference between revisions of "Cutaneous T-cell lymphoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://jco.ascopubs.org/content/28/11/1870.long" to "https://doi.org/10.1200/jco.2009.26.2386") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase III (" to "|Phase 3 (") |
||
| Line 21: | Line 21: | ||
|[https://doi.org/10.1200/jco.2009.26.2386 Prince et al. 2010 (L4389-11)] | |[https://doi.org/10.1200/jco.2009.26.2386 Prince et al. 2010 (L4389-11)] | ||
|NR | |NR | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
|[[Cutaneous_T-cell_lymphoma#Denileukin_diftitox_monotherapy|Denileukin diftitox]] | |[[Cutaneous_T-cell_lymphoma#Denileukin_diftitox_monotherapy|Denileukin diftitox]] | ||
| style="background-color:#d73027" |Inferior PFS | | style="background-color:#d73027" |Inferior PFS | ||
Revision as of 14:48, 12 February 2022
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main CTCL page for current regimens.
Relapsed or refractory
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Prince et al. 2010 (L4389-11) | NR | Phase 3 (C) | Denileukin diftitox | Inferior PFS |
References
- L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains verified protocol PubMed